With limited availability of CCR5Δ32-homozygous donors and the potential for immunological rejection, direct disruption of CCR5 by gene editing is needed to advance HIV-1/AIDS gene therapy [32, 34, 61, 62]. Here, CCR5 is linked to AIDS.